Black Bird Biotech(OTC) BBBT

Black Bird Biotech, Inc. operates in the biotechnology sector, focusing on innovative products for pest control and consumer goods. The company is known for its flagship product, MiteXstream, a plant-derived biopesticide designed to eliminate spider mites, alongside a diverse range of CBD-infused consumer products.

Products and Services

• MiteXstream, a biopesticide targeting spider mites
• Grizzly Creek Naturals brand offering CBD oils, gummies, and pet treats
• CBD-infused personal care items and hand sanitizers

Growth Outlook

• Participation in the Montana Hemp pilot program enhances market presence
• Expansion of product lines in the growing CBD market
• Increasing consumer demand for organic and natural pest control solutions

Financial Highlights

• Q3 2023 revenue of 3,937, a decrease from Q2's 12,922
• Net income for Q3 2023 was -131,227, reflecting ongoing operational challenges
• Cash and cash equivalents at 5,729 as of Q3 2023, down from 6,720 in Q2

Black Bird Biotech, Inc. is positioned within the Drug Manufacturers - Specialty & Generic industry, with a focus on sustainable and innovative solutions. The company’s flagship product, MiteXstream, represents a significant advancement in biopesticide technology, appealing to environmentally conscious consumers and businesses. The Grizzly Creek Naturals brand further diversifies the product portfolio, tapping into the rapidly expanding CBD market. Despite recent financial challenges, including a notable decline in revenue and net income, the company is actively pursuing growth opportunities. The participation in the Montana Hemp pilot program and the increasing demand for organic pest control solutions present avenues for future expansion. Investors may find interest in the company's potential to capitalize on these trends, despite the current financial hurdles. The focus on innovative, plant-based products aligns with broader market shifts towards sustainability and health-conscious consumer choices.